HR Execs on the Move

Neoleukin

www.neoleukin.com

 
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.neoleukin.com
  • 188 East Blaine Suite 450
    Seattle, WA USA 98102
  • Phone: 855.226.6447

Executives

Name Title Contact Details
Rob Bickford
Senior Director, Finance Profile
Sean Smith
Vice President, Finance Profile
Samantha Willing
Vice President of People Profile

Similar Companies

Pharmathene

Pharmathene, Inc is a Annapolis, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Abengoa

Abengoa applies innovative technology solutions for sustainability in the energy and environment sectors, generating electricity from renewable resources, converting biomass into biofuels and producing drinking water from sea water. Abengoa’s business is structured around three activities.

Advanced Environmental Testing And Abatement

Advanced Environmental Testing And Abatement is a Waterloo, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Complexa Inc

Complexa is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications.

Egenesis Bio

eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.